Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Language
Publication year range
1.
PLoS One ; 7(5): e37759, 2012.
Article in English | MEDLINE | ID: mdl-22662213

ABSTRACT

It has been previously described that p21 functions not only as a CDK inhibitor but also as a transcriptional co-repressor in some systems. To investigate the roles of p21 in transcriptional control, we studied the gene expression changes in two human cell systems. Using a human leukemia cell line (K562) with inducible p21 expression and human primary keratinocytes with adenoviral-mediated p21 expression, we carried out microarray-based gene expression profiling. We found that p21 rapidly and strongly repressed the mRNA levels of a number of genes involved in cell cycle and mitosis. One of the most strongly down-regulated genes was CCNE2 (cyclin E2 gene). Mutational analysis in K562 cells showed that the N-terminal region of p21 is required for repression of gene expression of CCNE2 and other genes. Chromatin immunoprecipitation assays indicated that p21 was bound to human CCNE2 and other p21-repressed genes gene in the vicinity of the transcription start site. Moreover, p21 repressed human CCNE2 promoter-luciferase constructs in K562 cells. Bioinformatic analysis revealed that the CDE motif is present in most of the promoters of the p21-regulated genes. Altogether, the results suggest that p21 exerts a repressive effect on a relevant number of genes controlling S phase and mitosis. Thus, p21 activity as inhibitor of cell cycle progression would be mediated not only by the inhibition of CDKs but also by the transcriptional down-regulation of key genes.


Subject(s)
Co-Repressor Proteins/metabolism , Cyclin-Dependent Kinase Inhibitor p21/metabolism , Mitosis/genetics , S Phase/genetics , Transcription, Genetic , Cell Line , Cluster Analysis , Computational Biology/methods , Cyclin-Dependent Kinase 2/metabolism , Cyclin-Dependent Kinase Inhibitor p21/chemistry , Cyclins/genetics , Gene Expression Profiling , Gene Expression Regulation , Humans , K562 Cells , Keratinocytes/metabolism , Promoter Regions, Genetic , Protein Binding
2.
Genes Dev ; 21(5): 562-77, 2007 Mar 01.
Article in English | MEDLINE | ID: mdl-17344417

ABSTRACT

Little is known about the regulation and function of the Notch1 gene in negative control of human tumors. Here we show that Notch1 gene expression and activity are substantially down-modulated in keratinocyte cancer cell lines and tumors, with expression of this gene being under p53 control in these cells. Genetic suppression of Notch signaling in primary human keratinocytes is sufficient, together with activated ras, to cause aggressive squamous cell carcinoma formation. Similar tumor-promoting effects are also caused by in vivo treatment of mice, grafted with keratinocytes expressing oncogenic ras alone, with a pharmacological inhibitor of endogenous Notch signaling. These effects are linked with a lesser commitment of keratinocytes to differentiation, an expansion of stem cell populations, and a mechanism involving up-regulation of ROCK1/2 and MRCKalpha kinases, two key effectors of small Rho GTPases previously implicated in neoplastic progression. Thus, the Notch1 gene is a p53 target with a role in human tumor suppression through negative regulation of Rho effectors.


Subject(s)
Carcinoma, Squamous Cell/genetics , Genes, Tumor Suppressor , Intracellular Signaling Peptides and Proteins/metabolism , Keratinocytes/metabolism , Protein Serine-Threonine Kinases/metabolism , Receptor, Notch1/genetics , Tumor Suppressor Protein p53/metabolism , Animals , Carcinoma, Squamous Cell/metabolism , Carcinoma, Squamous Cell/pathology , Cell Culture Techniques , Cell Differentiation , Cell Line, Tumor , Down-Regulation , Humans , Keratinocytes/cytology , Mice , Myotonin-Protein Kinase , Proto-Oncogene Proteins c-mdm2/antagonists & inhibitors , RNA, Small Interfering , Receptor, Notch1/metabolism , Signal Transduction , Skin Neoplasms/genetics , Skin Neoplasms/metabolism , Skin Neoplasms/pathology , Stem Cells/cytology , Tumor Suppressor Proteins/genetics , Tumor Suppressor Proteins/metabolism , rho-Associated Kinases
3.
J Biol Chem ; 281(41): 30463-70, 2006 Oct 13.
Article in English | MEDLINE | ID: mdl-16912042

ABSTRACT

p21 plays a dual role in keratinocyte growth and differentiation control. It restricts the number of keratinocyte stem cell populations while inhibiting the later stages of differentiation independently of the cell cycle. The molecular/biochemical mechanism for the differentiation suppressive function of p21 is unknown. Here we show that elevated p21 expression leads to activation of MAPK family members in a keratinocyte-specific and cell cycle-independent manner, and up-regulation of MAPK activity can explain the inhibitory effects of p21 on differentiation. p21 induces transcription of several genes with MAPK activation potential. Although several of these genes are induced by p21 in a MAPK-dependent manner, expression of IGF-I is induced upstream of MAPK activation. IGF-I stimulation is by itself sufficient to cause MAPK activation and inhibit differentiation and suppression of IGF-I signaling by knock down of the cognate receptor (IGF-R1), diminishing the ability of p21 to activate MAPK and suppress differentiation. Thus, in keratinocytes, the ability of p21 to suppress differentiation can be explained by cell type-specific activation of the MAPK cascade by transcriptional up-regulation of the IGF-I gene.


Subject(s)
Cyclin-Dependent Kinase Inhibitor p21/physiology , Gene Expression Regulation , Insulin-Like Growth Factor I/biosynthesis , Keratinocytes/cytology , Animals , Cell Cycle , Cell Differentiation , Cyclin-Dependent Kinase Inhibitor p21/metabolism , Enzyme Activation , Epidermis/metabolism , Insulin-Like Growth Factor I/genetics , Keratinocytes/metabolism , MAP Kinase Signaling System , Mice , Promoter Regions, Genetic , Transcription, Genetic
4.
Genes Dev ; 20(8): 1028-42, 2006 Apr 15.
Article in English | MEDLINE | ID: mdl-16618808

ABSTRACT

Notch signaling promotes commitment of keratinocytes to differentiation and suppresses tumorigenesis. p63, a p53 family member, has been implicated in establishment of the keratinocyte cell fate and/or maintenance of epithelial self-renewal. Here we show that p63 expression is suppressed by Notch1 activation in both mouse and human keratinocytes through a mechanism independent of cell cycle withdrawal and requiring down-modulation of selected interferon-responsive genes, including IRF7 and/or IRF3. In turn, elevated p63 expression counteracts the ability of Notch1 to restrict growth and promote differentiation. p63 functions as a selective modulator of Notch1-dependent transcription and function, with the Hes-1 gene as one of its direct negative targets. Thus, a complex cross-talk between Notch and p63 is involved in the balance between keratinocyte self-renewal and differentiation.


Subject(s)
Cell Differentiation/physiology , DNA-Binding Proteins/physiology , Keratinocytes/cytology , Receptor, Notch1/physiology , Trans-Activators/physiology , Tumor Suppressor Proteins/physiology , Animals , Base Sequence , DNA Primers , Humans , Mice , Promoter Regions, Genetic , RNA, Small Interfering , Transcription Factors
5.
J Biol Chem ; 280(45): 37725-31, 2005 Nov 11.
Article in English | MEDLINE | ID: mdl-16155000

ABSTRACT

Glucocorticoid-induced tumor necrosis factor receptor (GITR) is a member of the tumor necrosis factor receptor superfamily, is expressed in T lymphocytes, and exerts an anti-apoptotic function in these cells. We reported that GITR is also highly expressed in the skin, specifically in keratinocytes, and that it is under negative transcriptional control of p21(Cip1/WAF1), independently from the cell cycle. Although GITR expression is higher in p21-deficient keratinocytes and skin, it is down-modulated with differentiation and in response to UVB. The combined analysis of keratinocytes with increased GITR expression versus normal keratinocytes and skin of mice with a disruption of the GITR gene indicates that this protein protects keratinocytes from UVB-induced apoptosis both in vitro and in vivo.


Subject(s)
Apoptosis/radiation effects , Cyclin-Dependent Kinase Inhibitor p21/metabolism , Glucocorticoids/pharmacology , Keratinocytes/radiation effects , Receptors, Nerve Growth Factor/metabolism , Receptors, Tumor Necrosis Factor/metabolism , Transcription, Genetic , Ultraviolet Rays , Animals , Cells, Cultured , Cyclin-Dependent Kinase Inhibitor p21/genetics , Epidermal Cells , Epidermis/metabolism , Epidermis/radiation effects , Female , Gene Deletion , Glucocorticoid-Induced TNFR-Related Protein , Keratinocytes/cytology , Mice
6.
Genes Dev ; 19(12): 1485-95, 2005 Jun 15.
Article in English | MEDLINE | ID: mdl-15964998

ABSTRACT

In keratinocytes, the cyclin/CDK inhibitor p21(WAF1/Cip1) is a direct transcriptional target of Notch1 activation; loss of either the p21 or Notch1 genes expands stem cell populations and facilitates tumor development. The Notch1 tumor-suppressor function was associated with down-regulation of Wnt signaling. Here, we show that suppression of Wnt signaling by Notch1 activation is mediated, at least in part, by down-modulation of Wnts gene expression. p21 is a negative regulator of Wnts transcription downstream of Notch1 activation, independently of effects on the cell cycle. More specifically, expression of the Wnt4 gene is under negative control of endogenous p21 both in vitro and in vivo. p21 associates with the E2F-1 transcription factor at the Wnt4 promoter and causes curtailed recruitment of c-Myc and p300, and histone hypoacetylation at this promoter. Thus, p21 acts as a selective negative regulator of transcription and links the Notch and Wnt signaling pathways in keratinocyte growth control.


Subject(s)
Cell Cycle Proteins/metabolism , Proto-Oncogene Proteins/genetics , Receptors, Cell Surface/metabolism , Transcription Factors/metabolism , Animals , Basic Helix-Loop-Helix Transcription Factors , Cell Cycle , Cell Cycle Proteins/genetics , Cell Differentiation , Cell Division , Cells, Cultured , Cyclin-Dependent Kinase Inhibitor p21 , DNA-Binding Proteins/metabolism , Down-Regulation , E1A-Associated p300 Protein , E2F Transcription Factors , E2F1 Transcription Factor , Homeodomain Proteins/genetics , Homeodomain Proteins/metabolism , Keratinocytes/cytology , Keratinocytes/metabolism , Mice , Mice, Knockout , Nuclear Proteins/metabolism , Promoter Regions, Genetic , Proto-Oncogene Proteins c-myc/metabolism , RNA, Messenger/genetics , RNA, Messenger/metabolism , Receptor, Notch1 , Receptors, Cell Surface/genetics , Signal Transduction , Trans-Activators/metabolism , Transcription Factor HES-1 , Transcription Factors/genetics , Transcription, Genetic , Wnt Proteins , Wnt4 Protein
7.
Biochem Biophys Res Commun ; 313(4): 1030-6, 2004 Jan 23.
Article in English | MEDLINE | ID: mdl-14706646

ABSTRACT

The impact of embryonic enhanced green fluorescent protein (EGFP)-expression on development is not clear. In this study, we comprehensively assessed EGFP-expression pattern and its effect on early mouse development, following pronuclear-microinjection of the EGFP-transgene, containing chicken-beta-actin promoter and cytomegalovirus enhancer. Preimplantation embryos exhibited differential EGFP-expression patterns. While blastocyst development of non-expressing embryos was 77.3+/-1.8%, that of expressing embryos was only 43.9+/-1.6% (P<0.0001). Developmental competence of embryos negatively correlated (r=-0.99) with the levels of EGFP-expression. Faint-, moderate-, and intense-expressing embryos developed to 83.1+/-5.3%, 50+/-5%, and 9.5+/-3.9% blastocysts, respectively (P<0.002). Interestingly, blastocysts expressing faint-moderate levels of EGFP were developmentally competent through the post-implantation period and delivered viable transgenic 'green' mice, following embryo transfer. These results indicate that hyper-expression of EGFP affects preimplantation development and faint-moderate level of its expression is compatible with normal embryogenesis in the mouse.


Subject(s)
Embryonic and Fetal Development/genetics , Luminescent Proteins/genetics , Animals , Blastocyst/cytology , Blastocyst/metabolism , Embryo Transfer , Female , Fluorescence , Gene Expression Regulation, Developmental , Gene Transfer Techniques , Genetic Markers , Green Fluorescent Proteins , Mice , Mice, Inbred C57BL , Mice, Transgenic , Microinjections , Pregnancy , Recombinant Proteins/genetics
8.
Mol Reprod Dev ; 65(3): 269-77, 2003 Jul.
Article in English | MEDLINE | ID: mdl-12784248

ABSTRACT

To improve efficiency of transgenesis, we compared M16 and CZB embryo culture media, supporting development to blastocysts of FVB/N mouse pronuclear-eggs, microinjected with enhanced green fluorescent protein (EGFP) transgene. When EGFP-injected-eggs were cultured (120 hr), blastocyst development was significantly (P < 0.03) higher in M16 medium (72.5 +/- 2.4%) than that in CZB (13.2 +/- 4.3%) or CZBG (CZB with 5.6 mM glucose at 48 hr culture) (62.1 +/- 3.7%) media. Blastocyst development of noninjected embryos was higher in M16 (92.0 +/- 2.6%) and CZBG (83.9 +/- 3.9%) media than in CZB (31.9 +/- 2.8%) medium (P < 0.0001). However, percentages of morulae at 72 hr were comparable in all treatments. Developed blastocysts were better in M16 than in CZB or CZBG media. Consistent with this, mean cell number per blastocyst, developed from injected embryos, was significantly (P < 0.002) higher in M16 medium (79.6), than those in CZB (31.3) or CZBG media (60.7); similar with noninjected embryos. Cell allocation to trophectoderm (TE) and inner cell mass (ICM), i.e., TE:ICM ratio, for injected blastocysts in M16 (3.0) was less than (P < 0.05) those in CZB (4.2) and CZBG (4.4) media; similar with noninjected blastocysts. Moreover, blastocysts, developed in M16 and CZBG media, hatched, attached, and exhibited trophoblast outgrowth; 18% of them showed EGFP-expression. Importantly, blastocysts from M16 medium produced live transgenic "green" pups (11%) following embryo transfer. Taken together, our results indicate that supplementation of glucose, at 48 hr of culture (CZBG), is required for morula to blastocyst transition; M16 medium, containing glucose from the beginning of culture, is superior to CZB or CZBG for supporting development of biologically viable blastocysts from EGFP-transgene-injected mouse embryos.


Subject(s)
Blastocyst/physiology , Luminescent Proteins/genetics , Animals , Animals, Newborn , Blastocyst/cytology , Cell Survival , Culture Media , Embryo Transfer , Embryonic and Fetal Development/physiology , Gene Expression Regulation, Developmental , Green Fluorescent Proteins , Luminescent Proteins/metabolism , Mice , Mice, Inbred C57BL , Mice, Inbred Strains , Mice, Transgenic , Microinjections , Morula/cytology , Morula/physiology , Transfection/methods
9.
Biochem Biophys Res Commun ; 303(4): 994-1001, 2003 Apr 18.
Article in English | MEDLINE | ID: mdl-12684032

ABSTRACT

One of the limitations of transgenesis is low efficiency. In this study, we generated transgenic mice harboring the enhanced green fluorescent protein (EGFP) gene, under the control of chicken-beta-actin promoter and cytomegalovirus enhancer, using two approaches and compared their efficiencies. One involved culture of EGFP-injected embryos developing through EGFP-expressing "green" blastocysts, followed by their transfer to uterus. The second was oviductal-transfer of EGFP-injected-eggs. Embryo culture-based-transgenesis (ECBT) produced 100% transgenic mice, unlike the second approach. Moreover, ECBT required reduced number of recipients and markedly increased pregnancy rates. Of the nine founders, seven exhibited ubiquitous EGFP-expression, one (GU1) was a mosaic and the other (G18) was non-expressing. The molecular basis for this was attributed to repeat-induced gene silencing, since the G18 had a high copy number (approximately 99/genome) of the non-mutated and non-rearranged EGFP-transgene integrated at a single site. Our results show the superiority of ECBT over the conventional oviductal approach for generating transgenic "green" mice.


Subject(s)
Embryo Transfer , Luminescent Proteins/genetics , Mice, Transgenic , Animals , Animals, Newborn , Blastocyst/cytology , Cell Culture Techniques , Cell Nucleus/genetics , DNA/administration & dosage , Embryo, Mammalian/cytology , Female , Gene Dosage , Gene Silencing , Genotype , Green Fluorescent Proteins , Luminescent Proteins/metabolism , Mice , Microinjections , Microscopy, Fluorescence , Phenotype , Pregnancy
SELECTION OF CITATIONS
SEARCH DETAIL
...